Market Size of Global Bronchitis Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 3.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Bronchitis Treatment Market Analysis
The bronchitis treatment market is expected to grow at a CAGR of 3.6% over the forecast period (2022-2027).
The onset of the COVID-19 pandemic has led to a reduction in the number of patient visits that reduced the number of patients opting for bronchitis treatment, thereby impacting the market growth. For instance, as per a September 2020 published article titled, "Reduction in ambulatory visits for acute, uncomplicated bronchitis: an unintended but welcome result of the coronavirus disease 2019 (COVID-19) pandemic", the COVID-19 pandemic, while challenging for so many other aspects of antimicrobial stewardship, has led to an overall net reduction in ambulatory adults seeking care for bronchitis in the health system and has resulted in a dramatic reduction in antibiotic prescriptions for the condition. As a result, the impact of COVID-19 on the market was adverse during the initial phase of the pandemic.
Further, the major factors fueling the market's growth are the rise in the geriatric population with an augmented incidence of bronchitis, the growing prevalence of chronic obstructive pulmonary disease (COPD), an upsurge in the smoking populace, and rising levels of chemical pollutants.
The increased prevalence of COPD is a major factor driving the market growth. For instance, as per the House of Commons 2022, NHS Digital data shows that in 2020-2021, approximately 1.17 million people in England have been diagnosed with COPD, which is around 1.9% of the population. Also, as per a June 2021 update by the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. Thus, the increasing burden of COPD is leading to increasing demand for bronchitis treatment, as chronic bronchitis is one of the most common conditions leading to COPD, thereby contributing to the market growth.
However, the patent expiry of key drugs is a major factor hindering the bronchitis treatment market's growth.
